{
    "nctId": "NCT05966441",
    "briefTitle": "Role of Curcumin in Paclitaxel Induced PN",
    "officialTitle": "Evaluating the Effect of Curcumin in Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Chemotherapy-induced Peripheral Neuropathy",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "Evaluate the effect of Curcumin on the incidence and severity of paclitaxel-induced peripheral neuropathy (PIPN) in breast cancer patients.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Clinical diagnosis of early stage breast cancer with age \\> 18 years.\n* Performance status of the patients based on Eastern Cooperative Oncology Group (ECOG) from 0 to 2.\n* Patients must receive paclitaxel 80 mg/m2 weekly or 175 mg/m2 every 3 weeks for 12 weeks.\n* Patients clinical parameters should be (ANC \u2265 1500/mm3). Platelet count 100,000/mm3) (serum total bilirubin \\< 1.5 mg/dl) and (creatinine \\< 1.5 mg/dl).\n\nExclusion Criteria:\n\n* Patients they had any signs and symptoms of clinical neuropathy.\n* Diabetes mellitus\n* Patients receiving vitamin supplementation including vitamin B1, B6 and B12\n* Patients receiving antidepressants, anticoagulants, opioids or anticonvulsants\n* Patients had a hypersensitivity to curcumin.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}